Finnrick, an independent testing programme, publishes 14 assays for Mokemei Zhengzhou Biotechnology MKM: 9 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 5 did not. Most recent assay 23 Jul 2026.
Mokemei Zhengzhou Biotechnology MKM operates from China, listed by Finnrick as "Trading". Source: Finnrick, https://www.finnrick.com/vendors/mokemei-zhengzhou-biotechnology-mkm.
Mokemei Zhengzhou Biotechnology MKM is listed as active.
| Product | Assays | Result |
|---|---|---|
| Retatrutide | 10 | 7 passed, 3 failed |
| GHK-Cu | 4 | 2 passed, 2 failed |
Source: Finnrick, as published 2026-08-09. Pass and fail are Finnrick's classification against its own threshold, not ours.
| Status | Active |
|---|---|
| Vendor type | Research-use supplier |
These details were read from Mokemei Zhengzhou Biotechnology MKM's own website on 2026-08-10. Pages consulted:
Mokemei Zhengzhou Biotechnology MKM is listed as active and we hold 14 Finnrick assays (9 passing, 5 failing its purity threshold). That is evidence about the batches that were tested or published, not a guarantee about the vial you receive.
Yes. Finnrick, an independent testing programme, publishes 14 assays for Mokemei Zhengzhou Biotechnology MKM: 9 met its Purity focus threshold (at least 99.5% purity, no more than 35% dosage deviation) and 5 did not. Most recent assay 23 Jul 2026.
Popular peptides: Semaglutide, Tirzepatide, Retatrutide, BPC-157, CJC-1295, Ipamorelin.
Other reviewed vendors: Moli Peptide Review, Moltrix Peptides Review, Montreal Peptides Review.